Devyser Diagnostics AB
STO:DVYSR
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
71.6
139
|
| Price Target |
|
We'll email you a reminder when the closing price reaches SEK.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Devyser Diagnostics AB
Cash & Cash Equivalents
Devyser Diagnostics AB
Cash & Cash Equivalents Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Cash & Cash Equivalents | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
D
|
Devyser Diagnostics AB
STO:DVYSR
|
Cash & Cash Equivalents
kr262.9m
|
CAGR 3-Years
216%
|
CAGR 5-Years
103%
|
CAGR 10-Years
N/A
|
|
|
Biogaia AB
STO:BIOG B
|
Cash & Cash Equivalents
kr1.5B
|
CAGR 3-Years
2%
|
CAGR 5-Years
40%
|
CAGR 10-Years
N/A
|
|
|
Bonesupport Holding AB
STO:BONEX
|
Cash & Cash Equivalents
kr153.2m
|
CAGR 3-Years
-12%
|
CAGR 5-Years
3%
|
CAGR 10-Years
N/A
|
|
|
Vitrolife AB
STO:VITR
|
Cash & Cash Equivalents
kr925m
|
CAGR 3-Years
-42%
|
CAGR 5-Years
9%
|
CAGR 10-Years
23%
|
|
|
Swedish Orphan Biovitrum AB (publ)
STO:SOBI
|
Cash & Cash Equivalents
kr594m
|
CAGR 3-Years
41%
|
CAGR 5-Years
-11%
|
CAGR 10-Years
0%
|
|
|
BioArctic AB
STO:BIOA B
|
Cash & Cash Equivalents
kr611.6m
|
CAGR 3-Years
-15%
|
CAGR 5-Years
-8%
|
CAGR 10-Years
N/A
|
|
Devyser Diagnostics AB
Glance View
Devyser Diagnostics AB engages in the development, manufacture and sale of kits for genetic testing in routine diagnostics. The company is headquartered in Hagersten, Stockholm. The company went IPO on 2021-12-10. The products are used for complex deoxyribonucleic acid (DNA) testing in the areas of hereditary diseases, oncology, and post-transplantation monitoring in order to diagnose genetic diseases and target cancer treatment. The firm has since its inception developed and launched almost 30 products for routine diagnostic use, including Devyser Thrombophilia assay as well as Devyser Resolution XY for analysis of chromosomes X and Y. Devyser Diagnostics’ products are sold directly to the end customer or through hired distributors. The firm provides its products in more than 45 countries.
See Also
What is Devyser Diagnostics AB's Cash & Cash Equivalents?
Cash & Cash Equivalents
262.9m
SEK
Based on the financial report for Dec 31, 2023, Devyser Diagnostics AB's Cash & Cash Equivalents amounts to 262.9m SEK.
What is Devyser Diagnostics AB's Cash & Cash Equivalents growth rate?
Cash & Cash Equivalents CAGR 5Y
103%
Over the last year, the Cash & Cash Equivalents growth was -28%. The average annual Cash & Cash Equivalents growth rates for Devyser Diagnostics AB have been 216% over the past three years , 103% over the past five years .
You don't have any saved screeners yet
